阿尼利定 | 144-14-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 阿尼利定
• 中文别名: 苄胺哌替啶；苄胺度冷丁；胺苄哌替啶；阿尼里丁
• 英文名称: anileridine
• 英文别名: ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate
• CAS: 144-14-9
• 化学式: C₂₂H₂₈N₂O₂
• 分子量: 352.477
• InChiKey: LKYQLAWMNBFNJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  4

ADMET

代谢

肝脏的

Hepatic

来源:DrugBank

代谢

ANILERIDINE YIELDS P-AMINOPHENYLACETIC ACID & NORMEPERIDINE IN RATS. /FROM TABLE/ 阿尼勒啶在大鼠体内产生对氨基苯乙酸和诺美利定。/来自表格/

ANILERIDINE YIELDS P-AMINOPHENYLACETIC ACID & NORMEPERIDINE IN RATS. /FROM TABLE/

来源:Hazardous Substances Data Bank (HSDB)

代谢

肝脏的

Hepatic

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 毒性总结

阿片类药物的受体与G蛋白偶联，并通过激活效应蛋白的G蛋白，作为突触传递的正负调节因子。阿片类药物与受体的结合刺激了G蛋白复合物上GTP与GDP的交换。由于效应系统位于质膜内表面的腺苷酸环化酶和cAMP，阿片类药物通过抑制腺苷酸环化酶来降低细胞内cAMP。随后，抑制了痛觉神经递质如P物质、GABA、多巴胺、乙酰胆碱和去甲肾上腺素的释放。阿片类药物还抑制了血管加压素、生长抑素、胰岛素和胰高血糖素的释放。像阿尼利啶这样的阿片类药物关闭N型电压门控钙通道（OP2受体激动剂）并打开钙依赖性的内向整流钾通道（OP3和OP1受体激动剂）。这导致超极化并降低神经元兴奋性。

Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Opioids such as anileridine close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 致癌物分类

对人类不具有致癌性（未被国际癌症研究机构IARC列名）。

No indication of carcinogenicity to humans (not listed by IARC).

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 健康影响

医学问题可能包括肺充血、肝病、破伤风、心脏瓣膜感染、皮肤脓肿、贫血和肺炎。过量可能会导致死亡。

Medical problems can include congested lungs, liver disease, tetanus, infection of the heart valves, skin abscesses, anemia and pneumonia. Death can occur from overdose.

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 暴露途径

阿尼利啶可以通过所有给药途径被吸收。

Anileridine is absorbed by all routes of administration.

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 症状

过度暴露的症状包括头晕、出汗、发热感、口干、视力困难、瘙痒、欣快感、不安、紧张和兴奋。

Symptoms of overexposure include dizziness, perspiration, a feeling of warmth, dry mouth, visual difficulty, itching, euphoria, restlessness, nervousness and excitement have been reported.

来源:Toxin and Toxin Target Database (T3DB)

吸收、分配和排泄

• 吸收

阿尼利啶可以通过所有给药途径被吸收。

Anileridine is absorbed by all routes of administration.

来源:DrugBank

反应信息

• 作为反应物：
  描述：

  阿尼利定 在 乙酸酐 、 溶剂黄146 作用下， 生成 1-(4-acetylamino-phenethyl)-4-phenyl-piperidine-4-carboxylic acid ethyl ester
  参考文献：
  名称：

  Strong Analgesics. The Preparation of Some Ethyl 1-Aralkyl-4-phenylpiperidine-4-carboxylates¹

  摘要：

  DOI：

  10.1021/ja01565a050
• 作为产物：
  描述：

  4-苯基-4-乙氧甲酰哌啶盐酸盐 在 乙醇 、 镍 、 sodium carbonate 、 铂 、 正丁醇 作用下， 生成 阿尼利定
  参考文献：
  名称：

  Smirnowa et al., Meditsinskaya Promyshlennost SSSR, 1958, vol. 12, # 7, p. 31,34

  摘要：

  DOI：

文献信息

• [EN] IMIDAZOLIUM REAGENT FOR MASS SPECTROMETRY<br/>[FR] RÉACTIF D'IMIDAZOLIUM POUR SPECTROMÉTRIE DE MASSE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021234004A1

  公开（公告）日：2021-11-25

  The present invention relates to compounds which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said compounds.

  本发明涉及适用于质谱的化合物，以及利用该化合物进行分析物分子的质谱测定方法。
• [EN] ANTIBACTERIAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIBACTÉRIENS
  申请人：MASSACHUSETTS GEN HOSPITAL

  公开号：WO2019199979A1

  公开（公告）日：2019-10-17

  The present application provides compounds of formula: Methods of using these compounds for killing bacterial growth and treating bacterial infections are also provided.

  本申请提供了以下化合物的公式：还提供了使用这些化合物杀灭细菌生长和治疗细菌感染的方法。
• Controlled-release compositions containing opioid agonist and antagonist
  申请人：——

  公开号：US20020010127A1

  公开（公告）日：2002-01-24

  Controlled-release dosage forms containing an opioid agonist; an opioid antagonist; and a controlled release material release during a dosing interval an analgesic or sub-analgesic amount of the opioid agonist along with an amount of said opioid antagonist effective to attenuate a side effect of said opioid agonist. The dosage form provides analgesia for at least about 8 hours when administered to human patients. In other embodiments, the dose of antagonist released during the dosing interval enhances the analgesic potency of the opioid agonist.

  含有阿片激动剂、阿片拮抗剂和受控释放材料的控释剂型，其在给药间隔期间释放阿片激动剂的镇痛或亚镇痛量以及足以减轻所述阿片激动剂的副作用的阿片拮抗剂的量。当给予人类患者时，该剂型提供至少约8小时的镇痛作用。在其他实施例中，给药间隔期释放的拮抗剂剂量增强了阿片激动剂的镇痛效力。
• Kappa agonist compounds and pharmaceutical formulations thereof
  申请人：——

  公开号：US20030144272A1

  公开（公告）日：2003-07-31

  Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics are provided. The compounds of formulae I, II, IIA, III, IIIA, IIIB, IIIB-i, IV and IVA have the structure: 1 2 wherein R 1 , R 2 , R 3 , R 4 ; and X, X 4 , X 5 , X 7 , X 9 ; Y, Z and n are as described in the specification.

  提供具有kappa阿片受体激动剂活性的化合物，含有这些化合物的组合物以及使用它们作为镇痛剂的方法。 具有以下结构的化合物I、II、IIA、III、IIIA、IIIB、IIIB-i、IV和IVA： 1 2 其中 R 1 ，R 2 ，R 3 ，R 4 ；和 X，X 4 ，X 5 ，X 7 ，X 9 ； Y，Z和n如规范中所述。
• CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY
  申请人：Cerulean Pharma Inc.

  公开号：US20130196906A1

  公开（公告）日：2013-08-01

  Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.

  提供了关于使用CDP-治疗剂偶联物治疗疾病或紊乱的方法，例如自身免疫疾病、炎症性疾病、中枢神经系统紊乱、心血管疾病或代谢紊乱。还提供了CDP-治疗剂偶联物、包含CDP-治疗剂偶联物的颗粒以及包含CDP-治疗剂偶联物的组合物。

表征谱图